FDA’s New ‘Super Office’ Attacks Pharmaceutical Quality Risks
This article was originally published in The Gold Sheet
Executive Summary
Launched this month, CDER’s OPQ ‘Super Office’ blends the agency’s CMC review programs for new and generic drugs together, and focuses them on significant risks like the difficulty of release-testing modified-release drugs.